(Q35375761)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

6

Henry C Pitot

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

5

Alex A Adjei

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

4

Shauna L Hillman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Ming-Wen An

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sumithra J Mandrekar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Megan E Branda

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Richard M Goldberg

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

English

0 references

publication date

31 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

published in

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

6592-6599

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

Detecting an overall survival benefit that is derived from progression-free survival

11 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Response rates: a valuable signal of promising activity?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Alternate endpoints for screening phase II studies.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Can the pharmaceutical industry reduce attrition rates?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Evaluating the yield of medical tests

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195893

An alternative model for the evaluation of antitumor activity

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21880789

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21880789

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-11-0822

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21880789%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

PubMed publication ID

21880789

1 reference